2015
DOI: 10.3747/co.22.2322
|View full text |Cite
|
Sign up to set email alerts
|

Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline

Abstract: BackgroundThis systematic review addresses the question “What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)–positive breast cancer?”MethodsThe medline and embase databases were searched for the period January 2008 to May 2014. The Standards and Guidelines Evidence directory of cancer guidelines and the Web sites of major guideline organizations were also searched.ResultsSixty publications relevant to the targeted therapy portion of the syst… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
19
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(19 citation statements)
references
References 47 publications
0
19
0
Order By: Relevance
“…After antigen retrieval was performed, the tissue sections were covered with peroxide block solution for 5 min followed by incubation of primary antibody for 30 min, then the tissue sections covered with poly excel poly HRP and incubate for 30 min at room temperature, working solution and incubate for 5 min at room temperature, and finally hematoxyline stain was applied. Immunohistochemically stained sections were evaluated under a light microscope(leica DM500) independently by three pathologists by using the same scoring system established to evaluate HER2/NEU in breast cancer [18]. Score 0 no staining or membranous staining is observed in <10% of the tumor cells.…”
Section: Mukhtar Et Almentioning
confidence: 99%
“…After antigen retrieval was performed, the tissue sections were covered with peroxide block solution for 5 min followed by incubation of primary antibody for 30 min, then the tissue sections covered with poly excel poly HRP and incubate for 30 min at room temperature, working solution and incubate for 5 min at room temperature, and finally hematoxyline stain was applied. Immunohistochemically stained sections were evaluated under a light microscope(leica DM500) independently by three pathologists by using the same scoring system established to evaluate HER2/NEU in breast cancer [18]. Score 0 no staining or membranous staining is observed in <10% of the tumor cells.…”
Section: Mukhtar Et Almentioning
confidence: 99%
“…Other TKI selectively target non‐receptor tyrosine kinases, such as the Abelson murine leukemia viral oncogene homolog 1 (Abl) family of kinases c‐Abl and Bcr‐Abl . Tumor outgrowth can also be restrained by limiting oxygen, nutrients, and growth‐stimulating signals with specific monoclonal antibodies (mAb) against VEGF and human epidermal growth factor receptor 2 (HER‐2) …”
Section: Anti‐cancer Strategiesmentioning
confidence: 99%
“…18 Tumor outgrowth can also be restrained by limiting oxygen, nutrients, and growth-stimulating signals with specific monoclonal antibodies (mAb) against VEGF and human epidermal growth factor receptor 2 (HER-2). 19,20 Alternatively, targeted drugs can be designed against genetic mutations in cancer cells. A dominant mutation at the V600E amino acid of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) causes aberrant activation of mitogen-activated protein kinase (MAPK).…”
Section: Targeted Therapiesmentioning
confidence: 99%
“…In the nineties of the last century, the monoclonal antibody trastuzumab, targeted against the Her2 receptor, was introduced into the clinic and usually combined with paclitaxel. Since then, therapy of female breast cancer improved a lot, with a high 5-year survival (>90%), especially when the patients are estrogen or HER2 receptor positive [4].…”
Section: Precision Medicine In Cancer: Beyond Wishful Thinking?mentioning
confidence: 99%